A citation-based method for searching scientific literature

Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis, Pantelis Sarafidis. Curr Med Chem 2020
Times Cited: 11







List of co-cited articles
71 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
63

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
54

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
54

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
45

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
45

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916
45

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
45

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
Pantelis Sarafidis, Charles J Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque,[...]. Nephrol Dial Transplant 2019
70
45

The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Alexia Piperidou, Pantelis Sarafidis, Afroditi Boutou, Costas Thomopoulos, Charalampos Loutradis, Maria Eleni Alexandrou, Apostolos Tsapas, Asterios Karagiannis. J Hypertens 2019
10
40

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
700
36

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
87
36

Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
Konstantinos P Imprialos, Pantelis A Sarafidis, Asterios I Karagiannis. J Hypertens 2015
43
36

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
991
36

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
290
27

SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Ronald M Goldenberg, Lori D Berard, Alice Y Y Cheng, Jeremy D Gilbert, Subodh Verma, Vincent C Woo, Jean-François Yale. Clin Ther 2016
99
27


Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
724
27

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Erik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, Lennart Tonneijck, Mark M Smits, Anna L Emanuel, Andrea Bozovic, A H Jan Danser, Frank Geurts, Ewout J Hoorn,[...]. Kidney Int 2020
80
27

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent,[...]. Clin Kidney J 2018
85
27

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
227
27

Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Linda F Fried, Nicholas Emanuele, Jane H Zhang, Mary Brophy, Todd A Conner, William Duckworth, David J Leehey, Peter A McCullough, Theresa O'Connor, Paul M Palevsky,[...]. N Engl J Med 2013
614
27

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans-Henrik Parving, Barry M Brenner, John J V McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Akshay S Desai, Maria Nicolaides,[...]. N Engl J Med 2012
753
27

Global cardiovascular protection in chronic kidney disease.
Gema Ruiz-Hurtado, Pantelis Sarafidis, María S Fernández-Alfonso, Bernard Waeber, Luis M Ruilope. Nat Rev Cardiol 2016
21
27

Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
T D Filippatos, V Tsimihodimos, M S Elisaf. Expert Opin Pharmacother 2016
24
27

Cardiorenal disease development under chronic renin-angiotensin-aldosterone system suppression.
Pantelis A Sarafidis, Luis M Ruilope. J Renin Angiotensin Aldosterone Syst 2012
13
27


Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
Alan S Go, Glenn M Chertow, Dongjie Fan, Charles E McCulloch, Chi-yuan Hsu. N Engl J Med 2004
27

Advances in treatment of hyperkalemia in chronic kidney disease.
Pantelis A Sarafidis, Panagiotis I Georgianos, George L Bakris. Expert Opin Pharmacother 2015
20
27

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
370
27

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
27

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
412
18


Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update.
Aleksandra Novikov, Volker Vallon. Curr Opin Nephrol Hypertens 2016
45
18

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
198
18

Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
72
18

IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.
K Ogurtsova, J D da Rocha Fernandes, Y Huang, U Linnenkamp, L Guariguata, N H Cho, D Cavan, J E Shaw, L E Makaroff. Diabetes Res Clin Pract 2017
18


Glucose transport families SLC5 and SLC50.
Ernest M Wright. Mol Aspects Med 2013
132
18

Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis.
M W Savage, K K Dhatariya, A Kilvert, G Rayman, J A E Rees, C H Courtney, L Hilton, P H Dyer, M S Hamersley. Diabet Med 2011
141
18

The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
13
18


Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu,[...]. Lancet 2020
18

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.
Bo Li, Jing Yang, Faming Zhao, Lili Zhi, Xiqian Wang, Lin Liu, Zhaohui Bi, Yunhe Zhao. Clin Res Cardiol 2020
710
18

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, Yeming Wang, Bin Song, Xiaoying Gu,[...]. Lancet 2020
18

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.
Jose Luis Górriz, Juan F Navarro-González, Alberto Ortiz, Ander Vergara, Julio Nuñez, Conxita Jacobs-Cachá, Alberto Martínez-Castelao, Maria Jose Soler. Nephrol Dial Transplant 2020
10
20

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Biswajit Chowdhury, Albert Z Luu, Vincent Z Luu, M Golam Kabir, Yi Pan, Hwee Teoh, Adrian Quan, Sandra Sabongui, Mohammed Al-Omran, Deepak L Bhatt,[...]. Biochem Biophys Res Commun 2020
15
18

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
E J Lewis, L G Hunsicker, W R Clarke, T Berl, M A Pohl, J B Lewis, E Ritz, R C Atkins, R Rohde, I Raz. N Engl J Med 2001
18

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Jackson T Wright, George Bakris, Tom Greene, Larry Y Agodoa, Lawrence J Appel, Jeanne Charleston, DeAnna Cheek, Janice G Douglas-Baltimore, Jennifer Gassman, Richard Glassock,[...]. JAMA 2002
18

Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.
Pantelis A Sarafidis, Evangelos Memmos, Maria-Eleni Alexandrou, Aikaterini Papagianni. Curr Pharm Des 2018
6
33

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
239
18


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.